All Curated Mutation Sites in SARS-CoV-2 
Back to Mutation Home

 The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in SARS-CoV-2 related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.


Browse Data by Virus Gene/Protein/Region, Disease OR Description
*Please select one option you are interested in, the page will be automatically redirected.
     
     

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Show All
  
ORF1a
  
ORF1b
  
ORF3a
  
3CLpro
  
3'UTR
  
5'UTR
  
RBD
  
ORF7b-ORF8
  
upstream of N
  
Furin cleavage site
  
E
  
endoRNase
  
Exonuclease
  
S
  
NSP13
  
NSP3
  
M
  
Mpro
  
Methyltransferase
  
N
  
NSP14
  
NSP12
  
Non-coding region
  
NP
  
NS3
  
NS7a
  
NS7b
  
NS8
  
NSP5
  
NSP1
  
NSP10
  
NSP11
  
NSP15
  
NSP16
  
NSP2
  
NSP4
  
NSP6
  
NSP7
  
NSP8
  
NSP9
  
NTD
  
ORF8
  
ORF1ab
  
ORF9b
  
ORF10
  
ORF3
  
ORF6
  
ORF7a
  
ORF7b
  
ORF9
  
ORF9c
  
PLpro
  
RdRp
  
RBM
  
Replicase
  
RNA primase
  

Keyword: Cell line-36062074
ID PMID Mutation Gene/Protein/Region Encoding Gene/Protein Disease Description Detail
1 36062074 T95I
S
S
COVID-19
Cell line
G
R
C
L
View
2 36062074 G142D
S
S
COVID-19
Cell line
G
R
C
L
View
3 36062074 E154K
S
S
COVID-19
Cell line
G
R
C
L
View
4 36062074 L452R
S
S
COVID-19
Cell line
G
R
C
L
View
5 36062074 E484Q
S
S
COVID-19
Cell line
G
R
C
L
View
6 36062074 D614G
S
S
COVID-19
Cell line
G
R
C
L
View
7 36062074 P681R
S
S
COVID-19
Cell line
G
R
C
L
View
8 36062074 Q1071H
S
S
COVID-19
Cell line
G
R
C
L
View
Contents
Description

The table shows all curated mutation sites of SARS-CoV-2 in each literature

Table Description Column Note
D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.
G
The study mentioned the virus genotype/subtype information.
R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.
S
The study provided sequence information or accession numbers.
L
The study provided the geographic region/country of data origin.
C
The study provided clinical baseline information.
I
The study involved information related to immune.
T
The study involved host target genes.